This slide deck, presented by Aaron Goodman, MD, Hematologist/Oncologist and Associate Professor of Medicine at UC San Diego Health provides the latest insights on diagnosing T-cell lymphoma, including subtypes; efficacy and safety data for novel agents; tailoring treatment plans to individual patients; applying strategies to manage symptoms and optimize a patient’s quality of life; and much more!
This slide deck created by Amir Fathi, MD, Associate Professor of Medicine at Harvard Medical School, will highlight individualized treatment selection for patients with acute lymphoblastic leukemia (ALL), as well as recent efficacy and safety data for novel therapeutic strategies.
This slide deck created by Louis Diehl, MD, Professor of Medicine at Duke University Medical School, will feature strategies for incorporating predictive and prognostic markers, recent efficacy and safety data, and adverse event management strategies into treatment selection for patients with Hodgkin lymphoma (HL).
This slide deck will features insights on predictive and prognostic markers, emerging efficacy and safety data, strategies to optimize tolerability for patients receiving novel therapies for mantle cell lymphoma (MCL), and more in this case-based activity created by John Leonard, MD, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine.
This slide deck created by Mikkael Sekeres, MD, Chief of the Division of Hematology at the University of Miami Health System, will focus on predictive and prognostic markers for myelodysplastic syndromes (MDS), emerging data on novel therapies, and strategies to optimize safety and tolerability for patients with this disease.
This case-based slide deck, created by Morie Gertz, MD, Chair of General Internal Medicine at the Mayo Clinic in Minnesota, will show how to use predictive and prognostic markers to select treatment for patients with Waldenstrom macroglobulinemia (WM) and how to appraise emerging clinical trial data and adverse event management strategies for novel treatments. Start the activity now.
This slide deck, part of a two-part series, led by Sarah A. Holstein, MD, PhD, and Ashley E. Rosko, MD, will explore expert perspectives on practice-changing developments in the management of multiple myeloma and will also include updates from the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition. Part 1 of this series will take an in-depth look at the new standards in multiple myeloma classification at diagnosis, recent data on treatment regimens for newly diagnosed disease, and strategies for maintenance therapy.
This slide deck, part of a two-part series, led by by Sarah A. Holstein, MD, PhD, and Ashley E. Rosko, MD, will explore expert perspectives on practice-changing developments in the management of multiple myeloma and will also include updates from the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition.
Part 2 will familiarize practitioners with indications of multiple myeloma progression and timing of therapy, highlight practice-changing trials in the early and late relapse settings, and discuss how approaches to relapsed/refractory multiple myeloma are changing based on emerging data.
This slide deck, developed by Ulka N. Vaishampayan, MD, Professor of Oncology, Wayne State University, highlights evidence-based management of nonmetastatic and metastatic castration-resistant prostate cancer.
This slide deck, presented by Constance Visovsky, PhD, RN, ACNP, FAAN, Director and the Lewis & Leona Hughes Endowed Chair of the College of Nursing at the University of South Florida, will clarify the mechanism by which CDK4/6 inhibitors in combination with endocrine therapy are thought to overcome resistance to endocrine therapy in ER-positive metastatic breast cancer, including the data that led to the approval of abemaciclib in the early-stage breast cancer setting, as well as early and aggressive identification of side effects to minimize toxicity and much more!
This slide deck, presented by Julia LaBarbera, NP, Nurse Practitioner in Hematology/Oncology at UCLA Health in Santa Monica, will explore the uses of immune checkpoint inhibition, a therapeutic strategy which is moving to earlier settings in breast cancer, including preoperative therapy with pembrolizumab/chemotherapy. The discussion will include an overview of immune-mediated adverse events and how they can be graded and managed.
This slide deck, prestend by Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at Saint Luke’s Hospital, Kansas City, Missouri, will explain the benefit of PARP inhibitors for breast cancer in patients with germline BRCA mutations and will present the latest data justifying the recent approval of olaparib for adjuvant therapy in high-risk early breast cancer. She will also highlight the side effect profiles of PARP inhibitors and the importance of counseling patients about the side effects they may experience.
This slide deck, presented by Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at Saint Luke’s Hospital, Kansas City, Missouri, will explore the role of PI3K inhibitors for patients with a mutation in PIK3CA nd HR-positive, HER2-negative breast cancer, including alpelisib. She will explain how PI3K inhibition is thought to help overcome resistance to hormonal therapy for breast cancer and will review the safety concerns associated with PI3K agents.
This slide deck, presented by Julia A. LaBarbera, MSN, RN, AGACNP-BC, Nurse Practitioner in Hematology/Oncology at UCLA Health in Santa Monica, California, will discuss the increasing use of antibody-drug conjugates in breast cancer, including the approval of sacituzumab govitecan and the expanded approval of trastuzumab deruxtecan for HER2-low breast cancer, as well as monitoring for and managing the unique side effects of these highly efficacious treatments.
This slide deck, presented by Abbey Kaler, MS, APRN, FNP-C, Advanced Practice Registered Nurse in the Advanced Breast Cancer Program at the University of Texas MD Anderson Cancer Center, will review the current options for treatment of HER2-positive breast cancer using HER2-targeted monoclonal antibodies, including the advantages and disadvantages regarding the combination of trastuzumab/pertuzumab/hyaluronidase, the indications for margetuximab, and the latest guidance on managing cardiac and other adverse events with HER2-targeted monoclonal antibody therapy.
This slide deck, presented by Abbey Kaler, MS, APRN, FNP-C, Advanced Practice Registered Nurse in the Advanced Breast Cancer Program at the University of Texas MD Anderson Cancer Center, will review data on HER2 tyrosine kinase inhibitors, including tucatinib and neratinib, and will compare their activity and safety profiles in combination with other medications for breast cancer. She will also highlight the differing considerations for management of patients taking these drugs.